Amendment Dated: July 13, 2005

Reply to Examiner's Amendment of June 3, 2005

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (previously presented) A compound of the formula

wherein:

R¹ is a member selected from the group consisting of hydrogen, hydroxyl, amino, optionally-substituted alkyl and a ligand;

Y is a member selected from the group consisting of hydrogen, optionallysubstituted alkyl, optionally-substituted cycloalkyl, optionally-substituted aryl and optionally-substituted heteroaryl;

X is a member selected from the group consisting of optionally-substituted amino, oxygen, sulfur and a carbon single bond;

 R_2 is a member selected from the group consisting of C_6 - C_{26} alkyl, C_6 - C_{26} alkenyl, dialkylglycerolyl, dialkenylglycerolyl, diacylglycerolyl, 1,2-diacyl-sn-glycero-3phosphoethylenyl, 1,2-dialkoxy-3-aminopropanyl and 1,2-diacyloxy-3-aminopropanyl; R3 is a member selected from the group consisting of hydrogen, hydroxyl, amino, optionally-substituted alkyl and a ligand;

n is greater than 1; and i is greater than 1.

2. (previously presented) A compound in accordance with claim 1, wherein: Y is a member selected from the group consisting of hydrogen, optionally-substituted C₁-C₄ alkyl, optionally-substituted C₅-C₆ cycloalkyl and optionally-substituted phenyl;

Amendment Dated: July 13, 2005

Reply to Examiner's Amendment of June 3, 2005

X is a member selected from the group consisting of optionally-substituted amino, oxygen and sulfur:

 R^2 is a member selected from the group consisting of C_6 - C_{26} alkyl and C_6 - C_{26} alkenyl; n and i, added together, have a sum of 40 to 250.

3. (previously presented) A compound in accordance with claim 1, wherein:

Y is a member selected from the group consisting of hydrogen, optionally substituted Cl-C4 alkyl, optionally substituted Cs-C6 cycloalkyl and optionally substituted phenyl; X is optionally-substituted amino;

 R^2 is a member selected from the group consisting of C_6 - C_{26} alkyl and C_6 - C_{26} alkenyl; n and i added together have a sum of 40 to 250.

4. (previously presented) A compound in accordance with claim 1, wherein:

Y is a member selected from the group consisting of hydrogen, optionally substituted C1-C4 alkyl, optionally-substituted C5-C6 cycloalkyl and optionally-substituted phenyl; X is a carbon single bond;

R² is a member selected from the group consisting of dialkylglycerolyl, dialkenylglycerolyl, diacylglycerolyl, 1,2-diacyl-sn-glycero-3-phosphoethylenyl, 1,2-dialkoxy-3-aminopropanyl and 1,2-diacyloxy-3-aminopropanyl;

n and i added together have a sum of 40 to 250.

5. (previously presented) A compound in accordance with claim 1, wherein:

Y is a member selected from the group consisting of hydrogen, optionally substituted C₁-C₄ alkyl, optionally-substituted C5-C6 cycloalkyl and optionally-substituted phenyl;

X is a carbon single bond;

R² is a member selected from the group consisting of dialkylglycerolyl, dialkenylglycerolyl, diacylglycerolyl, 1,2-dialkoxy-3-aminopropanyl and 1,2-diacyloxy3-aminopropanyl; and n and i, added together, have a sum of 40 to 250.

6. (original) A compound in accordance with claim 1, wherein:

R³ is a ligand, said ligand being a member selected from the group consisting of a lipid, polyethylene glycol and a compound of the formula

$$- \left(\begin{array}{c} R^{4} \\ N - (CH_{2}CH_{2}O)_{m} - (CH_{2})_{p} - C - (NH_{H}C - C)_{q} \\ \end{array} \right)_{z} R^{5}$$

Page 3 of 9

Amendment Dated: July 13, 2005

Reply to Examiner's Amendment of June 3, 2005

wherein:

R⁴ is a member selected from the group consisting of hydrogen and alkyl; R is a member of the group selected from hydrogen, optionally substituted alkyl, optionally-substituted aryl and a side chain of an amino acid; R⁶ is a member selected from the group consisting of hydrogen, halogen, hydroxy, alkoxy, mercapto, hydrazino, amino and NR⁷R⁸, wherein R⁷ and R⁸ are independently hydrogen or alkyl; z is 4 to 80; m is 2 to 6; p is 1 to 4; and q is 0 or 1.

- 7. (original) A compound in accordance with claim 1, wherein:

 R is a member selected from the group consisting of C₁₀-C₁₈ alkyl and C₁₀-C₁₈ alkenyl.
- 8. (original) A compound in accordance with claim 1, wherein: R^2 is a member selected from the group consisting of dialkylglycerolyl and dialkenylglycerolyl, wherein said dialkyl groups are C_{10} - C_{18} dialkyl and said dialkenyl groups are C_{10} - C_{18} dialkenyl.
- 9. (original) A compound in accordance with claim 1, wherein: R^2 is a member selected from the group consisting of diacylglycerolyl and 1,2-diacyl-sn-glycero-3-phosphoethylenyl, wherein said diacyl groups are C_{10} - C_{18} diacyl.
- 10. (original) A compound in accordance with claim 1, wherein: R^2 is a member selected from the group consisting of C_{10} alkyl and C_{10} alkenyl.
- 11. (original) A compound in accordance with claim 1, wherein: R^2 is a member selected from the group consisting of dialkylglycerolyl and dialkenylglycerolyl, wherein said dialkyl groups are C_{10} dialkyl and said dialkenyl groups are C_{10} dialkyl and said dialkenyl groups are C_{10} dialkyl and said dialkenyl groups are C_{10} dialkenyl.
- 12. (original) A compound in accordance with claim 1, wherein: R^2 is a member selected from the group consisting of diacylglycerolyl and 1,2-diacyl-sn-glycero-3-phosphoethylenyl, wherein said diacyl groups are C_{10} acyl.
- 13. (previously presented) A pH-sensitive liposome, said liposome comprising a lipid and a compound of the formula

Amendment Dated: July 13, 2005

Reply to Examiner's Amendment of June 3, 2005

9704680104

wherein:

R¹ is a member selected from the group consisting of hydrogen, hydroxyl, amino, optionally-substituted alkyl and a ligand;

Y is a member selected from the group consisting of hydrogen, optionally-substituted alkyl, optionally-substituted cycloalkyl, optionally-substituted aryl and optionally-substituted heteroaryl;

X is a member selected from the group consisting of optionally-substituted amino, oxygen, sulfur a carbon single bond;

 R_2 is a member selected from the group consisting of C_6 - C_{26} alkyl, C_6 - C_{26} alkenyl, dialkylglycerolyl, dialkenylglycerolyl, diacylglycerolyl, 1,2-diacyl-sn-glycero-3-phosphoethylenyl, 1,2-dialkoxy-3-aminopropanyl and 1,2-diacyloxy-3-aminopropanyl; R3 is a member selected from the group consisting of hydrogen, hydroxyl, amino, optionally-substituted alkyl and a ligand;

n is greater than 1; and

i is greater than 1.

- 14. (original) A pH-sensitive liposome in accordance with claim 13 wherein said liposome is fusogenic.
- 15. (previously presented) A pH-sensitive liposome in accordance with claim 13 wherein said lipid is a member selected from the group consisting of phosphoglycerides, sphingolipids, phosphatidylcholine, phosphatidylethanolamine, lipolyamines, and cholesterol-based lipids.
- 16. (original) A pH-sensitive liposome in accordance with claim 15 wherein said lipid is a phosphatidylcholine.
- 17. (original) A pH-sensitive liposome in accordance with claim 16 wherein said phosphatidylcholine lipid is a member selected from the group consisting of distearoylphosphatidylcholine, dipalmitoylphosphatidylcholine, dimyristoylphosphatidylcholine,

Page 5 of 9

Amendment Dated: July 13, 2005

Reply to Examiner's Amendment of June 3, 2005

dilauroylphosphatidylcholine, dioleylphophatidylcholine, hydrogenated egg phosphatidylcholine, soy phosphatidylcholine, hydrogenated soy phosphatidylcholine, and egg phosphatidylcholine.

- 18. (original) A pH-sensitive liposome in accordance with claim 13 wherein said lipid is a mixture of egg phosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine and distearoylphosphotidylcholine.
- 19. (original) A pH-sensitive liposome in accordance with claim 13 further comprising cholesterol
- 20. (original) A pH-sensitive liposome in accordance with claim 19 wherein said lipid is egg phosphatidylcholine.
- 21. (original) A pH-sensitive liposome in accordance with claim 13 further comprising a bilayer stabilizing component.
- 22. (previously presented) A pH-sensitive liposome in accordance with claim 13 wherein said bilayer stabilizing component is a member selected from the group consisting of lipids, lipid derivatives, detergents, proteins, peptides, polyethylene glycol and N-(.omega.-N'-acetoxy-octa(14'amino-3',6',9',12'-tetraoxatetradecanoyl)) (ATTA).
- 23. (original) A pH-sensitive liposome in accordance with claim 22 wherein said polyethylene glycol has a molecular weight ranging from about 200 to 10,000.
- 24. (original) A pH-sensitive liposome in accordance with claim 22 wherein said ATTA has a molecular weight ranging from about 200 to 10,000.
- 25. (original) A pH-sensitive liposome in accordance with claim 22 wherein said polyethylene glycol has a molecular weight ranging from about 2,000 to 6,000.
- 26. (original) A pH-sensitive liposome in accordance with claim 22 wherein said ATTA has a molecular weight ranging from about 2,000 to 6,000.
- 27. (original) A pH-sensitive liposome in accordance with claim 13 wherein said compound is present at a concentration ranging from about 1 weight percent to about 22 weight percent of said lipid
- 28. (original) A pH-sensitive liposome in accordance with claim 27 wherein said compound is present at a concentration ranging from about 2 percent to about 20 percent of lipid in a weight to weight ratio.

Amendment Dated: July 13, 2005

Reply to Examiner's Amendment of June 3, 2005

- 29. (original) A pH-sensitive liposome in accordance with claim 27 wherein said compound is present at a concentration ranging from about 8 percent to about 10 percent of lipid.
- 30. (original) A pH-sensitive liposome in accordance with claim 19 wherein said cholesterol is present at a concentration ranging from about 0.02 mole percent to about 50 mole percent.
- 31. (original) A pH-sensitive liposome in accordance with claim 19 wherein said cholesterol is present at a concentration ranging from about 40 mole percent to about 45 mole percent.
- 32. (original) A pH-sensitive liposome in accordance with claim 13 wherein said liposome becomes permeable, unstable or fusogenic at a rate which can be controlled by pH 33. A pH-sensitive liposome in accordance with claim 13 wherein said liposome becomes destabilized at a rate which can be controlled by pH.
- 34. (original) A pH-sensitive liposome in accordance with claim 13 wherein said liposome becomes fusogenic at a rate which can be varied over a pH range of about 3 to about 10.
- 35. (original) A pH-sensitive liposome in accordance with claim 13 wherein said liposome becomes destabilized at a rate which can be controlled by varying Y
- 36. (original) A pH-sensitive liposome in accordance with claim 35 wherein Y is different in every other monomer n.
- 37. (original) A pH-sensitive liposome in accordance with claim 35 wherein Y is different in every other monomer i.
- 38. (currently amended) A method for delivering a therapeutic compound to a target cell comprising administering to a host containing said target cell a pH-sensitive liposome of claim 13.; said pH-sensitive liposome comprising: a lipid;

a compound of the formula

Amendment Dated: July 13, 2005

Reply to Examiner's Amendment of June 3, 2005

$$\begin{array}{c|c}
R^1 & CH_2 & C & CH_2 & C & R^3 \\
\hline
C=O & CH_2 & C & CH_2 & C & R^3 \\
X & OH & CH_2 & C & CH_2 & CH_2 & C & CH_2 & CH_2$$

- 39. (previously presented) A method in accordance with claim 38 further comprising a bilayer stabilizing component, wherein said bilayer stabilizing component is a member selected from the group consisting of lipids, lipid derivatives, detergents, proteins, peptides, polyethylene glycol and ATTA.
- 40. (original) A method in accordance with claim 38 wherein said liposome further comprises cholesterol.
- 41. (previously presented) A method in accordance with claim 38 wherein said liposome is fusogenic over a pH range from 4 to 7.
- 42. (original) A method in accordance with claim 38 wherein said liposome is administered intravenously.
- 43. (original) A method in accordance with claim 38 wherein said liposome is administered parenterally.
- 44. (original) A method in accordance with claim 38 wherein said liposome administered to said host is unilamellar.
- 45. (original) A method in accordance with claim 44 wherein said unilamellar liposome has a mean diameter of 0.05 microns to 0.45 microns.
- 46. (original) A method in accordance with claim 45 wherein said unilamellar liposome has a mean diameter of 0.05 microns to 0.2 microns.